Stem Cell Transplant or Cellular Therapy - Allogeneic

- **AML/MDS/ALL**
  - MDS Only
  - AML Only
  - AML/MDS Only
  - AML/MDS/ALL

- **Multiple Myeloma**

- **Severe Aplastic Anemia**

- **Multiple Diseases**

- **IRB# 10146**
  - Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate - 2 and high risk myelodysplastic syndrome.

- **IRB# 16943**
  - BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants.

- **IRB# 16995**
  - Phase 1/phase 2 study of Protume ex vivo mobilized peripheral blood cells.

- **IRB# 16189**
  - BEAM Conditioning for Allogeneic Hematopoietic Transplant for Sibling or Unrelated donors.

- **IRB# 11907**
  - Tests the drug PRO 140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.

- **IRB# 16943**
  - Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

- **IRB# 16982**
  - Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.

- **IRB# 9375**
  - Phase 1-2 BPX-501 T Cells after Partially Mismatched, Related Donor T Cell-Depleted Stem Cell Transplant.

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

3/4/2018